Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
100%
Anticoagulation Therapy
25%
Aortic Atherosclerosis
25%
Bleeding
25%
Brain Embolism
50%
Brain Hemorrhage
50%
Brain Infarction
25%
Brain Ischemia
50%
Cerebrovascular Accident
75%
Controlled Clinical Trial
50%
Dabigatran
75%
Paradoxical Embolism
25%
Patent Foramen Ovale
25%
Rivaroxaban
75%
Keyphrases
Anticoagulant Therapy
9%
Aortic Plaque
9%
Aspirin
36%
Brain Embolism
9%
Carotid Atherosclerotic Plaque
9%
Cerebral Embolism
9%
Cerebral Ischemia
9%
Clinical Tool
100%
Clinical Utility
9%
Cryptogenic Stroke
27%
Dabigatran
27%
Diagnostic Criteria
9%
Diagnostic Workup
9%
Efficacy Outcomes
9%
Embolic Stroke of Undetermined Source
100%
Hemorrhage Risk
9%
Hemorrhagic Stroke
9%
Heterogeneous Groups
9%
Indirect Analysis
9%
Intracranial Hemorrhage
9%
Ischemic Stroke Risk
9%
Ischemic Stroke Treatment
9%
Lack of Efficacy
18%
Major Bleeding
9%
Non-atherosclerotic
9%
Non-lacunar
9%
Occult
9%
Oral Anticoagulation
9%
Paradoxical Embolism
9%
Patent Foramen Ovale
9%
Progressive Cerebral Infarction
9%
Randomized Controlled Clinical Trial
18%
Rivaroxaban
27%
Safety Outcomes
9%
Single-photon Emission Computed Tomography (SPECT)
9%
Source Diagnostics
9%
Stroke Patients
18%
Treatment Strategy
9%
Twice Daily
9%
Medicine and Dentistry
Acetylsalicylic Acid
36%
Anticoagulant Therapy
9%
Anticoagulation
9%
Aortic Atherosclerosis
9%
Apoplexy
27%
Brain Embolism
18%
Brain Infarction
9%
Brain Ischemia
18%
Cerebral Hemorrhage
18%
Clinician
9%
Controlled Clinical Trial
18%
Dabigatran
27%
Embolic Stroke
100%
Major Bleeding
9%
Oral
9%
Paradoxical Embolism
9%
Patent Foramen Ovale
9%
Rivaroxaban
27%
Single-Photon Emission Computed Tomography
9%
Neuroscience
Aspirin
36%
Brain Ischemia
18%
Cerebral Hemorrhage
18%
Cerebral Infarction
9%
Cerebrovascular Accident
27%
Dabigatran
27%
Embolic Stroke
100%
Plaque
18%
Rivaroxaban
27%
Single-Photon Emission Computed Tomography
9%